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In patients with type 2 diabetes, sleep-disordered breathing is a widespread cause of deteriorated quality of life. However, robust
prevalence estimates for sleep-disordered breathing in patients with type 2 diabetes are limited due to scarce data. We
investigated sex diﬀerences in sleep-disordered breathing prevalence and its modulators in the DIACORE SDB substudy, a
sample of outpatient type 2 diabetes. 721 participants were tested for sleep-disordered breathing using a two-channel sleep
apnoea monitoring device. Patients were stratiﬁed according to the severity of sleep-disordered breathing, deﬁned as an apnoea-
hypopnoea index< 15, ≥15 to 29, and ≥30 events per hour as no/mild, moderate, and severe sleep-disordered breathing,
respectively. In the 679 analysed patients (39% women, age 66± 9 years, body mass index 31.0± 5.4 kg/m2), the prevalence
of sleep-disordered breathing was 34%. The prevalence of sleep-disordered breathing was higher in men than in women
(41% versus 22%, p < 0 001) and increased with age (15%, 21%, and 30% in women and 35%, 40%, and 47% in men in
those aged 18–59, 60–69, or ≥70, respectively; age trend p = 0 064 in women and p = 0 15 in men). In linear regression analysis,
age, BMI, and waist-hip ratio were associated with apnoea-hypopnoea index. Modulators for higher apnoea-hypopnoea index
seem to be similar in men and women.
1. Introduction
The International Diabetes Federation reports a worldwide
prevalence of diabetes mellitus of 8.8%, where type 2 diabetes
(T2D) makes up 87–91% in high-income countries and is
more common in men than in women [1]. Because of the
aging population and the increasing number of obese peo-
ple, the prevalence of T2D has become more than doubled
during the last three decades [2]. T2D may lead to several
late diabetic comorbidities like neuropathy, nephropathy,
and arteriosclerosis.
Sleep-disordered breathing (SDB), which is classiﬁed into
obstructive and central sleep apnoea, is characterised by
repetitive apnoeas and hypopnoeas, arousals from sleep as
well as alterations of heart rate, and elevated blood pressure
[3, 4]. Using an apnoea-hypopnoea index (AHI) cut-oﬀ
of ≥15/h, the prevalence of SDB ranges from 7 to 14% in
men and 2 to 7% in women, with increases over the last
two decades [5, 6].
It is well documented that treatment with positive airway
pressure eﬀectively suppresses obstructive sleep apnoea,
reduces sleep fragmentation, and restores normal sleep struc-
ture in patients with cardiac disease [7, 8]. It leads to signiﬁ-
cant improvement of daytime sleepiness and quality of life,
even in patients reporting only mild SDB-related symptoms
[9]. Previous studies investigated the association between
SDB and T2D. When focusing on moderate to severe forms
of SDB (AHI≥ 15/h) with an indication for treatment [4],
24 to 53% of patients with T2D suﬀer from SDB [10–12],
compared to 16% without T2D [10].
However, previous studies provide only limited informa-
tion about the prevalence and its modulators for SDB in
women with diabetes. Even if there was a nearly balanced
ratio in the number of men and women in most studies, they
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used smaller sample sizes [10–12] or included only selected
patients such as obese [12] or hospitalized patients [13]. Both
T2D and SDB are common in men and women, but often
underdiagnosed in women [14, 15]. We analysed a sample
of patients with T2D with an equal number of men and
women (61%/n = 412 men and 39%/n = 267 women) and
investigated sex diﬀerences in the prevalence of SDB as well
as modulators that were associated with SDB.
2. Material and Methods
2.1. Study Design. The investigated patients were participants
of the DIACORE (DIAbetes COhoRtE) SDB substudy
[16]. DIACORE is designed as a two-center, prospectively
planned study of T2D patients of European descent, with
a baseline survey conducted in 2010–2014 and recruitment
and ascertainment described previously [16, 17]. Brieﬂy,
written invitations were mailed to all T2D patients regis-
tered with ﬁve medical insurance companies in the respec-
tive year of the mailing and to all T2D outpatients of two
diabetologists in Regensburg that had visited the oﬃces
within the last 6 months of the mailing. Further, invita-
tions were sent to T2D patients who had received inpa-
tient treatment at the University Hospital Regensburg’s
Internal Medicine Departments within two years prior
to the mailing. Overall, 4226 patients contacted DIA-
CORE, of which 1226 did not fulﬁl the inclusion and
exclusion criteria. Diabetes status was ascertained by
assessing diabetes medication or by validating self-report.
Patients were subjected to a standardized online question-
naire, blood sampling, and physical examination at the two
study centers.
Of 1036 individuals invited to participate in the DIA-
CORE SDB substudy, 721 individuals with T2D from the
region around Regensburg, Germany, agreed to participate
and were tested with a two-channel ambulatory SDB mon-
itoring device (ApneaLink®, ResMed). In 679 patients (94%
of the 721 tested), complete SDB parameters were recorded.
Apparative monitoring for SDB was not performed in the
Mannheim study center. A two-year follow-up is currently
ongoing [17]; for this investigation, the cross-sectional
baseline dataset was used. The protocol, data protection
strategy, and study procedures were approved by the ethics
committees of both participating institutions and are in
accordance with the Declaration of Helsinki. Patients
participated in DIACORE only after providing informed
written consent.
2.2. Study Population. All T2D outpatients inhabiting the city
and county of Regensburg or Speyer were eligible for DIA-
CORE. Further inclusion criteria were the ability to fully
understand the study information and to provide written
informed consent, age≥ 18 years, and self-reported Caucasian
ethnicity. Exclusion criteria were chronic renal replacement
therapy (haemodialysis, peritoneal dialysis, or transplanta-
tion), history of active malignancy within the last ﬁve years,
autoimmune-disease potentially aﬀecting kidney function,
hemochromatosis, known pancreoprivic or self-reported type
1 diabetes, acute infection, fever, pregnancy, and chronic viral
hepatitis or HIV-infection. For the DIACORE SDB substudy,
patients were included if they consented to perform SDB
monitoring and excluded if they currently use positive airway
pressure therapy.
2.3. Assessment of SDB. Nasal ﬂow and pulse oximetry were
measured using the ApneaLink device (ResMed, Sydney,
Australia), which has been validated in several studies for
testing of SDB as described previously [18, 19] and is easy
to mount at home by the patient himself. Trained study per-
sonnel instructed participants in the use of the device in a
standardized fashion. ComparingApneaLink to the gold stan-
dard polysomnography, studies have reported a sensitivity of
73–94% and a speciﬁcity of 85–95% using an AHI cut-oﬀ
value of 15/h [19, 20]. AHI, oxygen desaturation index
(ODI), mean oxygen saturation (SpO2), and minimum SpO2
were documented. The default settings of the monitoring
device were used for the deﬁnitions of apnoea, hypopnoea,
and desaturation: apnoea was deﬁned as a≥ 80% decrease in
airﬂow for ≥10 seconds; hypopnoea was deﬁned as a decrease
in airﬂow by 50–80% versus baseline for≥10 seconds followed
by a≥ 4% decrease in oxygen saturation.
No or mild SDB was deﬁned as AHI< 15/h, moderate
SDB as AHI≥ 15/h to 29/h, and severe SDB was deﬁned as
AHI≥ 30/h. Periodic breathing (Cheyne-Stokes respiration)
was detected by automatic pattern recognition [21]. Due
to the lack of a chest band, a clear diﬀerentiation between
types of SDB, such as obstructive and central apnoea, was
not possible.
Additionally, subjective daytime sleepiness was assessed
using the self-administered validated Epworth Sleepiness
Scale (ESS). Individuals were asked to rate their likelihood
of falling asleep in several common situations. Scores range
from 0 (least sleepy) to 24 (sleepiest). Excessive daytime
sleepiness is deﬁned as a score of 11 or higher [22].
2.4. Statistical Analysis. Descriptive data are presented as
absolute and relative numbers or as mean± standard
deviation (SD). Normally distributed values of baseline
characteristics were evaluated with analysis of variance
(ANOVA). Diﬀerences in AHI between age groups were
tested with ANOVA and followed by pair-wise t-tests
(Bonferroni corrected level of signiﬁcance); sex diﬀerences
in AHI were tested with t-tests.
Linear regression models were used for continuous
variables and logistic regression for categorical variables, in
order to investigate the association between diﬀerent clinical
variables. Sex, age, body mass index (BMI), waist-hip ratio,
systolic blood pressure, and duration of T2D were included
as covariates in these models. Variables included in the linear
regression models were either normally distributed or trans-
formed prior to incorporation in the models. Results are
given as regression coeﬃcient B in linear models and as odds
ratio OR in logistic regression models with 95% conﬁdence
interval (CI); p values less than 0.05 were considered statisti-
cally signiﬁcant. Data were analysed using the SPSS statistical
software package (SPSS 20.0, IBM SPSS Statistics, Armonk,
New York, USA).
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3. Results
3.1. Patient Characteristics. Of the 721 patients with T2D
that were tested for SDB, 42 patients had incomplete data
recordings and could not be analysed (online Supplement
Figure S1). Of these, 679 participants were entered into the
analysis, of which 39% (n = 267) were women. Patients were
66± 9 years old, and BMI was 31.0± 5.4 kg/m2. Their gly-
cated haemoglobin (HbA1c) was 6.8± 1.1%, and the average
duration of T2D was 10.1± 8.0 years (Table 1). Women were
of about the same age compared to men, but had a higher
BMI (p < 0 001) and lower diabetes duration (p = 0 057)
than men.
Patients with severe SDB were older, predominantly
male, and had a signiﬁcant higher BMI as well as waist-hip
ratio compared to patients with no/mild SDB (p = 0 088,
p = 0 002, p < 0 001, and p < 0 001, resp.) (Table 2). Patients
with severe SDB had also a signiﬁcant larger waist cir-
cumference (p < 0 001). They showed lower high-density
lipoprotein cholesterol (HDL-C) as well as higher systolic
blood pressure, higher triglyceride levels, and more
severe insulin resistance quantiﬁed by homeostasis model
assessment (HOMA-IR [23]), but these values were not
statistically signiﬁcant. HbA1c levels and T2D duration
were comparable. Administration of incretin may have
implications on prognosis for myocardial infarction in
patients with T2D [24, 25]. In our study, there was no
diﬀerence in incretin administration between women
and men (Table 1) as well as between diﬀerent severities
of SDB (Table 2).
3.2. SDB Parameters. Table 2 presents the diﬀerent SDB
parameters and symptoms. ODI increased with higher sever-
ity of SDB. AHI was signiﬁcantly higher in men than in
women (mean 16 versus 11 per hour, resp., p < 0 001), also
when patients were divided into diﬀerent age groups
(Figure 1). Additionally, AHI increased between the diﬀerent
age groups (p = 0 102 in men, p = 0 045 in women, and
p = 0 006 overall, tested by ANOVA). Furthermore, patients
with moderate or severe SDB spent more than 2 hours with
SpO2< 90% (Table 2).
3.3. The Prevalence of SDB in Patients with T2D. The preva-
lence of SDB in our study sample was 22% in women, 41%
in men, and 34% overall. The prevalence of SDB was signiﬁ-
cantly higher in men compared to women overall (p < 0 001)
(Figure 2) and in each age group (p = 0 004, p = 0 001, and
p = 0 009) (Figure 3). Using an alternative deﬁnition of clin-
ically relevant SDB (AHI≥ 5/h+ESS≥ 11 or AHI≥ 15/h) led
to similar results (44% in men, 24% in women, and 36% over-
all; p < 0 001) (Figure 2). The prevalence of SDB in both men
and women increased with age, but this was statistically only
signiﬁcant in the whole sample (p = 0 151 in men; p = 0 069
in women; and p = 0 014 in either sex, tested by logistic
regression analysis) (Figure 3).
3.4. Modulators Associated with SDB in Patients with Type 2
Diabetes. Using logistic regression by sex, age≥ 70 years,
BMI≥ 30 kg/m2, waist-hip ratio≥ 0.85 in women and ≥0.9
in men [27] as well as systolic blood pressure≥ 130mmHg,
and T2D duration were analysed as covariates all in one
Table 1: Clinical characteristics of the 679 analysed subjects of the DIACORE baseline visit.
Characteristic Women (n = 267) Men (n = 412) All (n = 679)
Age [years] 65± 10 66± 8 66± 9
BMI [kg/m2] 31.9± 6.0 30.3± 4.8 31.0± 5.4
Waist-hip ratio 0.9± 0.07 1.00± 0.06 0.96± 0.08
Waist circumference [cm] 98± 14 102± 18 101± 17
Triglycerides [mg/dl] 163± 80 177± 156 171± 131
HDL-C [mg/dl] 58± 16 50± 13 53± 15
T2D duration [years] 9.4± 7.5 10.6± 8.3 10.1± 8.0
HbA1c [%] 6.8± 1.0 6.9± 1.2 6.8± 1.1
HbA1c [mmol/mol] 50.8± 12.6 51.9± 10.4 50.8± 11.5
HOMA-IR† 6.3± 8.5 6.0± 6.7 6.1± 7.4
Systolic BP [mmHg] 136± 18 139± 18 138± 18
Metabolic syndrome [%]∗ 83.5 68.8 74.6
Coronary artery disease [%] 9.7 28.4 21.1
Acute myocardial infarction [%] 6.0 15.8 11.9
Insulin [%] 24.0 28.6 26.8
Oral antidiabetics [%] 76.4 76.5 76.4
Sulfonylureas [%] 13.5 21.8 18.6
Incretins [%] 21.3 23.5 22.7
Data are expressed as percentage (%) for categorical variables and mean ± standard deviation for continuous variables. BMI = body mass index; HDL-C = high-
density lipoprotein cholesterol; T2D = type 2 diabetes; BP = blood pressure; HbA1c = glycated hemoglobin; HOMA-IR = homeostasis model assessment insulin
resistance (fasting, use of long-acting insulin). †n = 413. ∗Metabolic syndrome is deﬁned according to NCEP criteria [26].
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model to investigate an association with SDB (AHI≥ 15/h).
In women, age≥ 70 years (OR 1.95, 95% CI [1.04, 3.66],
p = 0 039) and systolic blood pressure≥ 130mmHg (OR
2.09, 95% CI [1.09, 4.02], p = 0 026) were signiﬁcantly
and independently associated with SDB. BMI≥ 30 kg/m2,
waist-hip ratio≥ 0.85, and T2D duration were not
signiﬁcantly associated with SDB (OR 1.56 [0.82, 2.97],
p = 0 175; OR 2.64 [0.97, 7.14], p = 0 057; and OR 0.99
[0.95, 1.04], p = 0 733, resp.).
In men, BMI≥ 30 kg/m2 (OR 2.27, 95% CI [1.49, 3.47],
p < 0 001) and T2D duration (per year; OR 1.03, 95% CI
[1.00, 1.05], p = 0 033) were signiﬁcant and independent
modulators were associated with SDB. Age≥ 70 years,
waist-hip ratio≥ 0.9, and systolic blood pressure≥ 130mmHg
were not signiﬁcantly associated with SDB in men (OR 1.52
[0.97, 2.37], p = 0 056; OR 1.05 [0.37, 2.96], p = 0 929; and
OR 1.10 [0.70, 1.73], p = 0 676, resp.).
Using a general regression model including both
sexes with sex, age≥ 70 years, BMI≥ 30 kg/m2, waist-hip
ratio≥ 0.85, systolic blood pressure≥ 130mmHg, and T2D
duration as covariates, besides age≥ 70 years (OR 1.65, 95%
CI 1.2, 2.4, p = 0 007) and BMI≥ 30 kg/m2 (OR 2.08, 95% CI
Table 2: Clinical and SDB parameters of the 679 analysed participants at the DIACORE baseline visit by SDB class.
No or mild SDB
(AHI< 15)
Moderate SDB
(AHI≥ 15 to 29)
Severe SDB
(AHI≥ 30) p value
∞ Moderate versus
no/mild SDB§
Severe versus
no/mild SDB§
Number of patients, n (%) 451 (66%) 163 (24%) 65 (10%)
Age [years] 64± 9 66± 8 67± 7 0.008 0.030 0.088
Female, n (%) 208 (46%) 43 (26%) 16 (25%) <0.001 <0.001 0.002
BMI [kg/m2] 30.4± 5.1 31.3± 5.2 34.0± 6.8 <0.001 0.139 <0.001
Waist-hip ratio 0.95± 0.08 0.98± 0.07 1.00± 0.08 <0.001 <0.001 <0.001
Waist circumference [cm] 99± 16 102± 16 112± 15 <0.001 0.054 <0.001
Triglycerides [mg/dl] 166± 125 181± 155 187± 107 0.273 0.597 0.699
HDL-C [mg/dl] 54± 16 51± 14 50± 13 0.016 0.080 0.080
T2D duration [years] 10± 7 12± 10 9± 7 0.001 0.001 1.000
HbA1c [%] 6.8± 1.1 6.9± 1.2 6.6± 0.7 0.111 0.867 0.340
HbA1c [mmol/mol] 51± 7 52± 8 49± 5 0.111 0.867 0.340
HOMA-IR† 5.6± 5.9 6.7± 9.1 7.9± 10.9 0.137 0.607 0.242
Systolic BP [mmHg] 137± 18 140± 19 141± 17 0.041 0.135 0.179
Metabolic syndrome [%] ∗ 71.8 78.4 84.6 0.038 0.290 0.079
Coronary artery disease [%] 16.0 23.3 20.0 0.101 0.083 0.235
Acute myocardial
infarction [%]
10.9 13.5 15.4 0.448 1.000 0.882
Insulin [%] 22.6 37.4 29.2 0.001 0.001 0.771
Oral antidiabetics [%] 77.6 74.2 73.8 0.601 1.000 1.000
Sulfonylureas [%] 19.3 18.4 13.8 0.573 1.000 0.877
Incretins [%] 24.4 18.4 21.5 0.288 0.355 1.000
SDB parameters
AHI [/h] 7± 4 21± 4 46± 12 0.001 <0.001 <0.001
ODI [/h] 7± 5 20± 5 41± 12 0.001 <0.001 <0.001
SpO2< 90% [min] 73± 106 125± 122 120± 85 0.001 <0.001 0.004
SpO2 [%] 93± 2 92± 2 92± 2 0.001 <0.001 <0.001
Min SpO2 [%] 80± 12 75± 16 74± 15 0.001 0.001 0.002
Nocturnal breathing
rate [/min]
15± 3 14± 3 12± 3 0.001 0.064 <0.001
Nocturnal heart rate [/min] 66± 9 66± 10 67± 10 0.667 1.000 1.000
ESS 5.1± 3.3 5.4± 3.6 5.9± 3.1 0.148 1.000 0.195
ESS≥ 11, n (%) 29 (6.5) 10 (6.4) 6 (9.5) 0.661 1.000 1.000
Nocturia (≥3x/night) [%] 64 (14%) 25 (16%) 11 (17%) 0.785 1.000 1.000
Data are expressed as percentage (%) for categorical variables and mean ± standard deviation for continuous variables. ∞Diﬀerence of parameters between the
three SDB groups assessed by chi-square tests for categorical variables and by ANOVA for continuous variables. §Diﬀerence of parameters between two SDB
groups assessed by post hoc analysis (Bonferroni). p < 0 05 was considered statistically signiﬁcant and marked in bold. SDB = sleep-disordered breathing;
BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; T2D = type 2 diabetes; BP = blood pressure; HbA1c = glycated hemoglobin; HOMA-
IR = homeostasis model assessment insulin resistance (fasting, use of long-acting insulin); AHI = apnoea-hypopnoea index; ODI = oxygen desaturation
index; SpO2 = peripheral oxygen saturation; ESS = Epworth Sleepiness Scale.
†n = 413. ∗Metabolic syndrome is deﬁned according to NCEP criteria [26].
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1.5, 3.0, p < 0 001), only male sex was independently associ-
ated with SDB (OR 2.57, 95% CI 1.7, 3.8, p < 0 001).
WHR≥ 0.85, systolic blood pressure≥ 130mmHg, and T2D
duration were not signiﬁcantly associated with SDB in either
sex (OR 1.87, 95% CI [0.8, 4.4], p = 0 156; OR 1.37, 95% CI
[1.0, 2.0], p = 0 091; and OR 1.02, 95% CI [0.99, 1.04],
p = 0 106, resp.).
In regression models with all covariates listed above plus
including interaction terms of each of the other covariates
with sex, no interaction with sex was detected (interaction
terms for age≥ 70 years, BMI≥ 30 kg/m2, WHR≥ 0.85,
systolic blood pressure≥ 130mmHg, and T2D duration:
p = 0 527, p = 0 333, p = 0 999, p = 0 128, and p = 0 280,
resp.). Thus, modulators for SDB seem to be similar in
men and women.
3.5. Modulators Associated with AHI in Patients with Type 2
Diabetes. Linear regression analysis (Table 3) showed that a
higher AHI was independently associated with higher age,
higher BMI, and higher waist-hip ratio in women. In men,
only age and BMI, but not waist-hip ratio, were signiﬁcantly
associated with AHI.
In the entire sample, male sex, age, BMI, and waist-hip
ratio were associated with a higher AHI independent of the
other covariates. Systolic blood pressure and T2D duration
showed no signiﬁcant association with AHI in either sex.
Adding an interaction term of waist-hip ratio with sex to
the regression model stated above, no interaction with sex
was detected (interaction p = 0 503). Thus, modulators for a
higher AHI seem to be similar in men and women.
Both, metabolic syndrome and SDB are known to pro-
mote cardiovascular disease and arrhythmia [28–30]. Due
to this, we added metabolic syndrome to the multivariable
analysis and it appeared as a signiﬁcant modulator of
AHI in the whole sample (B=5.139; 95% CI 2.913, 7.364;
p < 0 001) as well as in women (B=5.099; 95% CI 1.422,
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Figure 1: Apnoea-hypopnoea index (AHI) in men and women of
the total sample (n = 679) and of diﬀerent age groups (18–59,
60–69, and ≥70 years) (n = 164, n = 286, and n = 229), stating mean
values in the bar and including standard errors and p values
from t-tests. AHI was signiﬁcantly higher in men than in women
in the whole sample as well as in diﬀerent age groups.
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Figure 2: Bar charts showing the prevalence of sleep-disordered
breathing (SDB) and clinically relevant SDB (AHI≥5/h + ESS≥ 11
or AHI≥ 15/h) in 412 men and 267 women (%); p values assessed
by chi-square tests. n = 679. SDB as well as clinically relevant SDB
was signiﬁcantly more present in men than in women.
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Figure 3: Bar charts with the prevalence of sleep-disordered
breathing (SDB) in men and women in diﬀerent age groups (%);
p values were assessed by chi-square tests. n = 679. SDB was
signiﬁcantly more present in men than in women in each age group.
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8.776; p = 0 007) and in men (B=5.186; 95% CI 2.350,
8.022; p < 0 001).
4. Discussion
The present study investigating SDB in 679 patients with
T2D obtained several key ﬁndings. First, moderate to severe
SDB, deﬁned as AHI≥ 15/h, is present in more than a third
of our patients with T2D. Second, the prevalence of moderate
to severe SDB increases with age and is more common in
men than in women yielding a prevalence of 40% and 21%
in our sample of 60 to 69-year-old men or women, respec-
tively. Third, age, BMI, and waist-hip ratio are signiﬁcant
and independent modulators were associated with higher
AHI. There were no signiﬁcant diﬀerences of these eﬀects
between men and women.
The prevalence of SDB in community samples was mod-
estly lower than in samples of patients with T2D. In obese
participants of the same age group with a BMI (30.0 to
39.9 kg/m2) as seen in our sample, 29% of men and 14% of
women have SDB [5].
Our results of 34% of patients with T2D with SDB are
consistent with the seven prior studies including more than
150 patients with T2D and using polysomnography or SDB
monitoring devices for diagnosis of SDB (Table 4). Diﬀer-
ences in prevalence could be explained by diﬀerences in par-
ticipant recruiting, patient characteristics, deﬁnitions of sleep
apnoea, or methods of monitoring for SDB (Table 4 and
online Supplement Table S2).
Some studies showed higher prevalence estimates than
our study [12, 31] (Table 4). The reason for these higher
prevalence estimates might be explained by a higher BMI of
participants (Foster et al. BMI= 36.5± 5.8 kg/m2, Schober
et al. BMI= 32.6± 6.7 kg/m2, and BMI=31.0± 5.4 kg/m2 in
the DIACORE SDB substudy) [12, 31] since obesity is a
known risk factor for SDB [1, 32, 33].
Other studies showed lower prevalence estimates. The
patient populations of those studies had signiﬁcantly
lower BMI (25.1± 3.6 kg/m2) [34] or were signiﬁcantly
younger [10, 13].
Similar to previous studies [31, 35], we found a higher
prevalence of SDB in men than in women.
In previous studies, varied information about the mod-
ulators of SDB in patients with diabetes has been pre-
sented. Lam et al. found that male sex, higher age as
well as BMI, and diastolic blood pressure were indepen-
dently associated with AHI [35]. In the present study,
age, BMI, and waist-hip ratio were signiﬁcantly associated
with AHI.
Even if there were no signiﬁcant diﬀerences in modu-
lators for a higher AHI between the sexes, waist-hip ratio
showed an association with AHI in women in the DIA-
CORE substudy. This ﬁnding might be explained by the
diﬀerences in the distribution of bodily fat between the
sexes. In women, fat accumulation in the hip region is
more common compared to men [36]. Therefore, it is
possible that the eﬀect of a pathologically increased
waist-hip ratio on AHI could be higher in women than
in men.
Table 3: Linear regression analysis: factors associated with AHI in the total population, in 267 women and in 412 men.
Variable
Univariable analysis Multivariable analysis
B (95% CI) p value B (95% CI) p value
Total population (n = 679)
Female sex −4.75 (−6.74, −2.76) <0.001 −3.54 (−6.06, −1.02) 0.006
Age [per 10 years] 1.70 (0.59, 2.81) 0.003 2.55 (1.40, 3.70) <0.001
BMI [per 5 units] 2.99 (2.10, 3.88) <0.001 3.48 (2.53, 4.44) <0.001
Waist-hip ratio [per 0.1 unit] 4.48 (3.25, 5.71) <0.001 2.35 (0.77, 3.94) 0.004
Systolic BP 0.08 (0.03, 0.13) 0.004 0.02 (−0.04, 0.07) 0.508
T2D duration 0.09 (−0.04, 0.21) 0.165 −0.004 (−0.13, 0.12) 0.952
Women (n = 267)
Age [per 10 years] 1.92 (0.49, 3.35) 0.009 2.35 (0.83, 3.87) 0.003
BMI [per 5 units] 2.00 (0.87, 3.13) 0.001 2.05 (0.88, 3.21) 0.001
Waist-hip ratio [per 0.1 units] 3.24 (1.13, 5.35) 0.003 2.29 (0.18, 4.40) 0.034
Systolic BP 0.08 (0.01, 0.16) 0.037 0.03 (−0.05, 0.11) 0.446
T2D duration 0.06 (−0.13, 0.25) 0.527 −0.02 (−0.02, 0.17) 0.826
Men (n = 412)
Age [per 10 years] 1.41 (−0.19, 3.01) 0.084 2.76 (1.09, 4.43) 0.001
BMI [per 5 units] 4.75 (3.45, 6.06) <0.001 5.25 (3.73, 6.77) <0.001
Waist-hip ratio [per 0.1 units] 4.92 (2.71, 7.12) <0.001 1.59 (−0.77, 3.94) 0.185
Systolic BP 0.06 (−0.01, 0.14) 0.091 0.01 (−0.06, 0.09) 0.739
T2D duration 0.07 (−0.09, 0.23) 0.393 0.01 (−0.15, 0.17) 0.882
AHI = apnoea-hypopnoea index; B = unstandardized regression coeﬃcient; 95% CI = 95% conﬁdence interval; BMI = body mass index; T2D
duration = duration of type 2 diabetes; BP = blood pressure.
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There is evidence that diabetes and its level of severity
could contribute to the development of SDB and its worsen-
ing [38, 39]. Although this was only a cross-sectional analy-
sis, our data do not support this hypothesis, since HbA1c,
HOMA-IR, and the duration of diabetes were not associated
with the presence or severity of SDB.
On the other hand, there is evidence that SDB may
contribute to impaired glucose metabolism [40]. Studies
investigating the eﬀects of treatment of obstructive sleep
apnoea with continuous positive airway pressure show
diﬀerent results. In a randomized controlled trial, this therapy
signiﬁcantly improved glucose tolerance [41]. However, other
studies did not ﬁnd any changes in glycaemic control [42, 43].
Particularly, T2D results in very high economic and
social costs [1]. Due to the evidence of a mutual impact of
T2D and SDB, the high proportion of SDB in patients with
T2D, and the clinical relevance, monitoring for SDB might
be proﬁtable as this proportion of patients could beneﬁt from
SDB therapy.
Especially patients with typical symptoms like daytime
sleepiness, heavy snoring or already occurring apnoeas
should be tested for SDB [33, 44], because treatment of
SDB with continuous positive airway pressure improves
quality of life and daytime sleepiness, even in patients with
mild SDB-related symptoms [9, 45]. Additionally, physi-
cians treating patients with SDB should also consider the
possibility of T2D and should initiate appropriate tests or
measures [33].
The strengths of our study are the large sample size
and high-resolution phenotyping of a T2D outpatient
cohort with a comparable number of men and women
(61%/n = 412 versus 39%/n = 267), thus enabling us to
investigate eﬀects speciﬁc to sex and using multivariable
modelling. It expands on the knowledge from previous
studies that were restricted to a clinically more severe
diabetes status.
There are also some limitations that warrant discussion:
ﬁrst, although the use of portable respiratory devices
instead of inpatient overnight polysomnography is well
established and validated for assessment of SDB [18, 19],
we cannot distinguish between obstructive and central
sleep apnoea due to simpliﬁed monitoring. Second, left
ventricular ejection fraction and heart failure were not
evaluated in DIACORE, so we cannot report on their
implications on the present study. Third, our sample might
not be fully representative of an overall T2D patient group,
because we did not standardize prevalence estimates to a
speciﬁc population.
5. Conclusions
More than one-third of patients with T2D had moderate to
severe sleep-disordered breathing, which was more common
in men than in women. Higher age, higher BMI, and higher
waist-hip ratio were associated with higher AHI. Modulators
for higher AHI were similar in men and in women. Testing
for SDB in patients with type 2 diabetes is recommended
and vice versa.
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